PS Medical Specialists Ltd 07997503 false 2025-04-01 2026-03-31 2026-03-31 The principal activity of the company is to be provide medical services. Digita Accounts Production Advanced 6.30.9574.0 true true 07997503 2025-04-01 2026-03-31 07997503 2026-03-31 07997503 core:FinancialAssetsCostLessImpairment core:Non-currentFinancialInstruments 2026-03-31 07997503 core:FinancialAssetsDesignatedFairValueThroughProfitOrLoss core:Non-currentFinancialInstruments 2026-03-31 07997503 core:CurrentFinancialInstruments 2026-03-31 07997503 core:CurrentFinancialInstruments core:WithinOneYear 2026-03-31 07997503 core:MotorVehicles 2026-03-31 07997503 core:OtherPropertyPlantEquipment 2026-03-31 07997503 bus:SmallEntities 2025-04-01 2026-03-31 07997503 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 07997503 bus:FullAccounts 2025-04-01 2026-03-31 07997503 bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 07997503 bus:RegisteredOffice 2025-04-01 2026-03-31 07997503 bus:Director1 2025-04-01 2026-03-31 07997503 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 07997503 core:MotorVehicles 2025-04-01 2026-03-31 07997503 core:OtherPropertyPlantEquipment 2025-04-01 2026-03-31 07997503 core:PlantMachinery 2025-04-01 2026-03-31 07997503 core:Vehicles 2025-04-01 2026-03-31 07997503 countries:England 2025-04-01 2026-03-31 07997503 2025-03-31 07997503 core:MotorVehicles 2025-03-31 07997503 core:OtherPropertyPlantEquipment 2025-03-31 07997503 2024-04-01 2025-03-31 07997503 2025-03-31 07997503 core:CurrentFinancialInstruments 2025-03-31 07997503 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 07997503 core:MotorVehicles 2025-03-31 07997503 core:OtherPropertyPlantEquipment 2025-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 07997503

PS Medical Specialists Ltd
Annual Report and Unaudited Financial Statements
for the Year Ended 31 March 2026

PS Medical Specialists Ltd

Contents

Balance Sheet | 1
Notes to the Unaudited Financial Statements | 2 to 6

PS Medical Specialists Ltd

(Registration number: 07997503)
Balance Sheet as at 31 March 2026

| Note | 2026 £ | 2025 £
Fixed assets |  |  |
Tangible assets | 5 | 18,966 | 26,539
Other financial assets | 6 | 461,068 | 306,488
|  | 480,034 | 333,027
Current assets |  |  |
Debtors | 7 | 196,697 | 215,508
Cash at bank and in hand |  | 950,774 | 799,004
|  | 1,147,471 | 1,014,512
Creditors: Amounts falling due within one year | 8 | (133,252) | (129,149)
Net current assets |  | 1,014,219 | 885,363
Total assets less current liabilities |  | 1,494,253 | 1,218,390
Provisions for liabilities |  | (4,742) | (6,635)
Net assets |  | 1,489,511 | 1,211,755
Capital and reserves |  |  |
Called up share capital | 9 | 100 | 100
Retained earnings |  | 1,489,411 | 1,211,655
Shareholders' funds |  | 1,489,511 | 1,211,755

For the financial year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’.

Approved and authorised by the Board on 27 April 2026 and signed on its behalf by:

......................................... Dominic Paviour Director

PS Medical Specialists Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

1 | General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
80-83 Long Lane
London
EC1A 9ET
United Kingdom

These financial statements were authorised for issue by the Board on 27 April 2026.

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

PS Medical Specialists Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.
Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class | Depreciation method and rate
Plant and machinery | 33% reducing balance
Motor vehicle | 20% straight-line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

PS Medical Specialists Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3 | Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2025 - 2).

4 | Profit before tax

Arrived at after charging/(crediting)

| 2026 £ | 2025 £
Depreciation expense | 9,452 | 9,541

PS Medical Specialists Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

5 | Tangible assets

| Motor vehicles £ | Other tangible assets £ | Total £
Cost or valuation
At 1 April 2025 | 36,956 | 16,410 | 53,366
Additions | - | 1,879 | 1,879
At 31 March 2026 | 36,956 | 18,289 | 55,245
Depreciation
At 1 April 2025 | 14,782 | 12,045 | 26,827
Charge for the year | 7,391 | 2,061 | 9,452
At 31 March 2026 | 22,173 | 14,106 | 36,279
Carrying amount
At 31 March 2026 | 14,783 | 4,183 | 18,966
At 31 March 2025 | 22,174 | 4,365 | 26,539

6 | Other financial assets (current and non-current)

| Financial assets at fair value through profit and loss £ | Financial assets at cost less impairment £ | Total £
Non-current financial assets
Cost or valuation
At 1 April 2025 | 287,802 | 18,628 | 306,430
Fair value adjustments | 27,731 | - | 27,731
Additions | 110,000 | 16,907 | 126,907
At 31 March 2026 | 425,533 | 35,535 | 461,068
Impairment
Carrying amount
At 31 March 2026 | 425,533 | 35,535 | 461,068

PS Medical Specialists Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

7 | Debtors

Current | 2026 £ | 2025 £
Trade debtors | 191,438 | 200,482
Prepayments | - | 3,457
Other debtors | 5,259 | 11,569
| 196,697 | 215,508

8 | Creditors

Creditors: amounts falling due within one year

| 2026 £ | 2025 £
Due within one year |  |
Trade creditors | 18,331 | 12,314
Taxation and social security | 109,985 | 110,809
Accruals and deferred income | 2,350 | 2,863
Other creditors | 2,586 | 3,163
| 133,252 | 129,149

9 | Share capital

Allotted, called up and fully paid shares

| 2026 | 2025
| No. | £ | No. | £
Ordinary share A of £1 each | 50 | 50 | 50 | 50
Ordinary share B of £1 each | 50 | 50 | 50 | 50
| 100 | 100 | 100 | 100